Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Trillium Therapeutics stock

TRIL.TO
CA89620X5064
A12FG3

Price

18.51
Today +/-
+0
Today %
+0 %

Trillium Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Trillium Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Trillium Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Trillium Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Trillium Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Trillium Therapeutics Stock Price History

DateTrillium Therapeutics Price
11/19/202118.51 undefined
11/18/202118.41 undefined

Trillium Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Trillium Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Trillium Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Trillium Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Trillium Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Trillium Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Trillium Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Trillium Therapeutics’s growth potential.

Trillium Therapeutics Revenue, EBIT and net profit per share

DateTrillium Therapeutics RevenueTrillium Therapeutics EBITTrillium Therapeutics Net Income
2025e0 undefined0 undefined-94.32 M undefined
2024e0 undefined0 undefined-92.21 M undefined
2023e0 undefined0 undefined-91.94 M undefined
2022e0 undefined0 undefined-93.46 M undefined
2021e3,396.6 undefined0 undefined-96.31 M undefined
2020150,000 undefined-61.46 M undefined-59.35 M undefined
2019120,000 undefined-32.29 M undefined-38.08 M undefined
20180 undefined-37.43 M undefined-32.87 M undefined
20170 undefined-31.58 M undefined-34.75 M undefined
20160 undefined-25.18 M undefined-23.95 M undefined
20150 undefined-16.19 M undefined-11.52 M undefined
20140 undefined-11.32 M undefined-11.66 M undefined
20130 undefined-4.17 M undefined-4.16 M undefined
20120 undefined-1.09 M undefined-1.06 M undefined
20110 undefined-2.5 M undefined-3.21 M undefined
20100 undefined-3.82 M undefined-4.18 M undefined
20090 undefined-4.07 M undefined-4.08 M undefined
20080 undefined-5.57 M undefined-5.21 M undefined
20070 undefined-5.04 M undefined-5.08 M undefined
20060 undefined-4.02 M undefined-4.2 M undefined
20050 undefined-2.56 M undefined-2.7 M undefined
20040 undefined-670,000 undefined-730,000 undefined

Trillium Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200420052006200720082009201020112012201320142015201620172018201920202021e2022e2023e2024e2025e
0000000000000000000000
----------------------
----------------------
0000000000000000000000
0-2-4-5-5-4-4-3-1-4-11-11-23-34-32-38-59-96-93-91-92-94
--100.0025.00--20.00--25.00-66.67300.00175.00-109.0947.83-5.8818.7555.2662.71-3.13-2.151.102.17
0.040.180.180.240.370.460.520.60.621.364.26.647.829.7713.9125.2684.600000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Trillium Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Trillium Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20042005200620072008200920102011201220132014201520162017201820192020
                                 
0.44.80.910.85.34.32.92.61.431.122.562.737.66533.422.7291.2
000100000000000500800300900
00000000000000000
00000000000000000
0.10.20.20.50.30.10000.10.90.90.30.80.80.36.4
0.551.111.45.64.42.92.61.431.223.463.637.966.33523.3298.5
00.10.10.1000000.10.20.62.42.31.62.31.5
00000000000000000
00000000000000000
21.81.61.61.21.10.9001.40.40.18.86.44.20.80.8
00000000000000000
0000000000010010010010000
21.91.71.71.21.10.9001.50.60.811.38.85.93.12.3
2.56.92.813.16.85.53.82.61.432.72464.449.275.140.926.4300.8
                                 
1.27.87.924.221.126.630.330.831.65551.397.9101.2157.9167.1173.2492.3
0.10.40.61.21.21.92.52.82.93.15.26.39.212.12123.138.6
-0.8-3.6-7.7-14.5-16.4-23.4-29.2-31.2-33.1-26.2-35.5-42.2-67.1-107.5-149.3-190-244.4
00000000000000-8.2-7.6-7.6
00000000000000000
0.54.60.810.95.95.13.62.41.431.9216243.362.530.6-1.3278.9
0000000.20.10.10.11.410.800.51.67.9
0000000.10.20.10.21.41.2308.311.99.6
0.10.20.41.5000000.40.30.30.60.3113.43.9
00000000000000000
00000000000000000
0.10.20.41.5000.30.30.20.73.12.54.40.39.826.921.4
000000000300200200100100000
00000000000000000
1.61.61.20000000.10.10.31.810.40.80.6
1.61.61.20000000.40.30.51.91.10.40.80.6
1.71.81.61.5000.30.30.21.13.436.31.410.227.722
2.26.42.412.45.95.13.92.71.63324.46549.663.940.826.4300.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Trillium Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Trillium Therapeutics's financial health and stability.

Assets

Trillium Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Trillium Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Trillium Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Trillium Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20042005200620072008200920102011201220132014201520162017201820192020
0-2-4-5-5-4-4-3-1-4-11-11-23-34-32-38-59
00000000000033200
000000000000-20000
00000000001025-110
00000001002-23411036
00000000000000000
00000000000000000
0-1-3-4-4-3-3-1-1-2-6-14-17-20-30-24-22
000000000000-20000
000000000000-9-44239-35
000000000000-7-43239-35
00000000000000000
00000000000000000
160130121033057048013290
160130121033057048013290
-----------------
00000000000000000
04-39-4-1-10-130-547-27-17-70233
00000000000000000
00000000000000000

Trillium Therapeutics stock margins

The Trillium Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Trillium Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Trillium Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Trillium Therapeutics's sales revenue. A higher gross margin percentage indicates that the Trillium Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Trillium Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Trillium Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Trillium Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Trillium Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Trillium Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Trillium Therapeutics Margin History

Trillium Therapeutics Gross marginTrillium Therapeutics Profit marginTrillium Therapeutics EBIT marginTrillium Therapeutics Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
2022e0 %0 %0 %
2021e0 %0 %-2.84 M %
20200 %-40,973.33 %-39,566.66 %
20190 %-26,908.33 %-31,733.33 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %
20040 %0 %0 %

Trillium Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Trillium Therapeutics earnings per share therefore indicates how much revenue Trillium Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Trillium Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Trillium Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Trillium Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Trillium Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Trillium Therapeutics Revenue, EBIT and net profit per share

DateTrillium Therapeutics Sales per ShareTrillium Therapeutics EBIT per shareTrillium Therapeutics Earnings per Share
2025e0 undefined0 undefined-0.84 undefined
2024e0 undefined0 undefined-0.83 undefined
2023e0 undefined0 undefined-0.82 undefined
2022e0 undefined0 undefined-0.84 undefined
2021e0 undefined0 undefined-0.86 undefined
20200 undefined-0.73 undefined-0.7 undefined
20190 undefined-1.28 undefined-1.51 undefined
20180 undefined-2.69 undefined-2.36 undefined
20170 undefined-3.23 undefined-3.56 undefined
20160 undefined-3.22 undefined-3.06 undefined
20150 undefined-2.44 undefined-1.73 undefined
20140 undefined-2.7 undefined-2.78 undefined
20130 undefined-3.07 undefined-3.06 undefined
20120 undefined-1.76 undefined-1.71 undefined
20110 undefined-4.17 undefined-5.35 undefined
20100 undefined-7.35 undefined-8.04 undefined
20090 undefined-8.85 undefined-8.87 undefined
20080 undefined-15.05 undefined-14.08 undefined
20070 undefined-21 undefined-21.17 undefined
20060 undefined-22.33 undefined-23.33 undefined
20050 undefined-14.22 undefined-15 undefined
20040 undefined-16.75 undefined-18.25 undefined

Trillium Therapeutics business model

Trillium Therapeutics Inc is a Canadian biotech company specializing in the development of cancer treatments. The company was founded in 2005 and is based in Mississauga, Ontario. Trillium Therapeutics is involved in various areas of research. One of its key focuses is the development of immunotherapies for cancer treatment. The company is working on the discovery and development of novel targeted immunotherapies that aim to specifically target tumors and utilize the body's immune system to fight cancer. Another focus of Trillium Therapeutics is the development of cancer drugs targeting specific gene mutations. These drugs are intended to inhibit or kill cancer cells by specifically targeting the genetically altered cells. Trillium Therapeutics is also involved in the discovery and development of drugs for the treatment of immuno-oncological diseases, which are diseases where the body's immune system fights against its own cells, such as autoimmune diseases. The business model of Trillium Therapeutics is based on the research and development of innovative cancer drugs. The company collaborates closely with leading cancer centers and clinics to identify and test new therapeutic approaches. Trillium Therapeutics has a number of products and therapies in development. One example is TTI-621, an immunotherapy that aims to recognize and kill tumor cells. TTI-621 is currently in clinical trials for the treatment of T-cell lymphomas and glioblastomas, a type of brain tumor, and has shown promising results. Another product that Trillium Therapeutics is working on is TTI-622. It is also an immunotherapy that focuses on inhibiting T-cells to support controlled tumor growth. TTI-622 is currently in clinical trials in patients with advanced cancer. The company is also working on a number of preclinical programs aimed at expanding treatment options for cancer patients. These programs target various biological targets, including immunomodulation, induction of apoptosis, and inhibition of DNA repair. Trillium Therapeutics has received several awards and recognitions in recent years, including inclusion in the Russell 3000 Index, being named the top biotechnology company on the BioCentury Future Leaders List, and being recognized as one of the top 10 most exciting biotech companies in Canada. Overall, Trillium Therapeutics is a leading biotech company focused on the development of innovative cancer therapies. The company is at the forefront of technology and collaborates closely with leading cancer centers and clinics to develop products that can improve the lives of cancer patients. Trillium Therapeutics is one of the most popular companies on Eulerpool.com.

Trillium Therapeutics SWOT Analysis

Strengths

Trillium Therapeutics Inc has several strengths that contribute to its success in the biotechnology industry. One significant strength is its strong research and development capabilities. The company invests heavily in scientific research, enabling it to develop innovative drug candidates and stay at the forefront of medical advancements.

Furthermore, Trillium benefits from strategic partnerships with leading pharmaceutical companies, which provide financial support, expertise, and access to additional resources. These collaborations enhance Trillium's ability to conduct clinical trials, accelerate drug development, and ultimately bring new therapies to market.

Weaknesses

Despite its strengths, Trillium Therapeutics Inc also faces certain weaknesses. One notable weakness is its heavy reliance on a few key drug candidates. If any of these candidates fail to gain regulatory approval or do not perform as expected in clinical trials, it could significantly impact Trillium's financial stability and growth prospects.

Another weakness is Trillium's limited marketing and distribution capabilities. The company heavily relies on its partners for commercialization activities, which may restrict its ability to effectively promote and distribute its products in the market.

Opportunities

Trillium Therapeutics Inc operates in an industry with abundant growth opportunities. The increasing prevalence of various diseases and the rising demand for innovative therapeutics present a significant opportunity for the company to expand its product portfolio and capture a larger market share.

Additionally, advancements in technology and the growing interest in personalized medicine open doors for Trillium to develop targeted therapies and personalized treatment solutions. Expanding into emerging markets and exploring partnerships with research institutions further broadens the company's potential for growth.

Threats

Trillium Therapeutics Inc faces several threats that could hinder its success. One prominent threat is intense competition within the biotechnology industry. Other companies, including both established firms and emerging startups, are also striving to develop breakthrough therapies. Trillium must continuously innovate and stay ahead in order to maintain its competitive edge.

Moreover, regulatory challenges and strict approval processes can introduce uncertainties and delays in bringing new drugs to market. Adverse regulatory decisions or changes in healthcare policies may impact the company's revenue streams and overall business operations.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Trillium Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Trillium Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Trillium Therapeutics shares outstanding

The number of shares was Trillium Therapeutics in 2024 — This indicates how many shares 84.6 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Trillium Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Trillium Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Trillium Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Trillium Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Trillium Therapeutics stock splits

In Trillium Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Trillium Therapeutics.

Trillium Therapeutics shareholders

%
Name
Stocks
Change
Date
5.13343 % New Enterprise Associates (NEA)5,736,363-850,0009/30/2021
5.10089 % Avoro Capital Advisors LLC5,700,00009/30/2021
4.67795 % Eventide Asset Management, LLC5,227,376-4,282,6249/30/2021
4.24143 % BlackRock Institutional Trust Company, N.A.4,739,590223,9229/30/2021
2.92755 % Magnetar Capital Partners LP3,271,3903,271,3909/30/2021
2.80997 % Pentwater Capital Management LP3,140,0003,140,0009/30/2021
2.79485 % Frazier Healthcare Partners3,123,10709/30/2021
2.28814 % Gabelli Funds, LLC2,556,8852,229,7859/30/2021
2.11806 % Omni Partners US LLC2,366,8242,366,8249/30/2021
1.72129 % ARP Americas LP1,923,4551,923,4559/30/2021
1
2
3
4
5
...
10

Most common questions regarding Trillium Therapeutics

What values and corporate philosophy does Trillium Therapeutics represent?

Trillium Therapeutics Inc represents a strong set of values and corporate philosophy. They prioritize innovation, integrity, and excellence in their work. With a focus on developing innovative therapies, Trillium aims to improve the lives of patients. Their corporate philosophy emphasizes collaboration, transparency, and accountability throughout their operations. Trillium also values the wellbeing of their employees, fostering a supportive and inclusive work environment. By embodying these principles, Trillium Therapeutics seeks to make a significant impact in the field of biotechnology and bring hope to patients in need.

In which countries and regions is Trillium Therapeutics primarily present?

Trillium Therapeutics Inc primarily operates in Canada, with its headquarters located in Mississauga, Ontario. As a clinical-stage immuno-oncology company, Trillium Therapeutics focuses on developing innovative therapies for the treatment of cancer. While their primary presence is in Canada, Trillium Therapeutics also maintains collaborations and partnerships with various international organizations and institutions. These collaborations enable the company to conduct research and clinical trials in different countries and regions, further enhancing their global reach and impact in the field of immuno-oncology.

What significant milestones has the company Trillium Therapeutics achieved?

Trillium Therapeutics Inc has achieved various significant milestones. Some noteworthy accomplishments include the initiation of Phase 1 clinical trials for their innovative therapies, successful completion of preclinical studies, and establishment of strategic collaborations with leading pharmaceutical companies. Additionally, Trillium Therapeutics Inc has received regulatory designations, such as Orphan Drug Designations, recognizing the potential of their treatments in addressing rare disorders. These achievements demonstrate the company's commitment to advancing novel therapies and its ability to attract industry recognition and partnerships. Trillium Therapeutics Inc continues to pursue further milestones in its mission to improve patient outcomes through scientific innovation and collaboration.

What is the history and background of the company Trillium Therapeutics?

Trillium Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer patients. Founded in 2004 and headquartered in Mississauga, Ontario, Canada, Trillium has been dedicated to advancing its proprietary scientific platforms and expertise. The company specializes in the discovery and development of targeted immunotherapies designed to enhance the immune system's ability to combat cancerous cells. With a robust pipeline of novel drug candidates, Trillium Therapeutics Inc. continues to invest in cutting-edge research to address unmet medical needs and improve patients' lives.

Who are the main competitors of Trillium Therapeutics in the market?

The main competitors of Trillium Therapeutics Inc in the market include leading biopharmaceutical companies such as Gilead Sciences, Inc., Bristol Myers Squibb Company, and Novartis AG. These companies are actively involved in the field of oncology and are known for their expertise in developing innovative therapies for cancer treatment. Trillium Therapeutics Inc competes with these industry players to bring novel and effective therapies to the market, focusing on its unique approach to immune-oncology and its dedication to improving patients' lives.

In which industries is Trillium Therapeutics primarily active?

Trillium Therapeutics Inc is primarily active in the pharmaceutical industry.

What is the business model of Trillium Therapeutics?

Trillium Therapeutics Inc. is a biopharmaceutical company specializing in the development of innovative therapies for cancer patients. Their business model revolves around the research, development, and commercialization of targeted immunotherapies. By leveraging their expertise and proprietary technologies, Trillium Therapeutics is focused on designing innovative treatments that harness the power of the immune system to fight against various types of tumors. Their strategic collaborations and partnerships further strengthen their ability to advance these therapies, ensuring a comprehensive approach to cancer treatment. Trillium Therapeutics Inc. is dedicated to improving patient outcomes through their cutting-edge immunotherapy solutions.

What is the P/E ratio of Trillium Therapeutics 2025?

The Trillium Therapeutics P/E ratio is -16.6.

What is the P/S ratio of Trillium Therapeutics 2025?

The Trillium Therapeutics P/S ratio is 0.

What is the Quality Investing of Trillium Therapeutics?

The Quality Investing for Trillium Therapeutics is 2/10.

What is the revenue of Trillium Therapeutics 2025?

The revenue cannot currently be calculated for Trillium Therapeutics.

How high is the profit of Trillium Therapeutics 2025?

The expected Trillium Therapeutics profit is -94.32 M USD.

What is the business model of Trillium Therapeutics

Trillium Therapeutics Inc. is a biopharmaceutical company focused on the development of innovative immunotherapies for the treatment of cancer and other serious diseases. The company's main areas of focus include oncology immunotherapy and genomics and proteomics research. Trillium's products aim to strengthen the body's immune system and increase its ability to recognize and destroy cancer cells. The company is also collaborating with large pharmaceutical companies to develop new therapies and products. Trillium's business model is geared towards developing effective immunotherapies and bringing them to market quickly. The company has a strong pipeline of promising products and is committed to growth through research and development and partnerships.

What is the Trillium Therapeutics dividend?

Trillium Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Trillium Therapeutics pay dividends?

The dividend cannot currently be calculated for Trillium Therapeutics or the company does not pay out a dividend.

What is the Trillium Therapeutics ISIN?

The ISIN of Trillium Therapeutics is CA89620X5064.

What is the Trillium Therapeutics WKN?

The WKN of Trillium Therapeutics is A12FG3.

What is the Trillium Therapeutics ticker?

The ticker of Trillium Therapeutics is TRIL.TO.

How much dividend does Trillium Therapeutics pay?

Over the past 12 months, Trillium Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Trillium Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Trillium Therapeutics?

The current dividend yield of Trillium Therapeutics is .

When does Trillium Therapeutics pay dividends?

Trillium Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Trillium Therapeutics?

Trillium Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Trillium Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Trillium Therapeutics located?

Trillium Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Trillium Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Trillium Therapeutics from 1/15/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.

When did Trillium Therapeutics pay the last dividend?

The last dividend was paid out on 1/15/2025.

What was the dividend of Trillium Therapeutics in the year 2024?

In the year 2024, Trillium Therapeutics distributed 0 USD as dividends.

In which currency does Trillium Therapeutics pay out the dividend?

The dividends of Trillium Therapeutics are distributed in USD.

All fundamentals about Trillium Therapeutics

Our stock analysis for Trillium Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trillium Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.